Home CONTACT Neoplasma 2005 Neoplasma Vol.52, p.302-306, 2005

Journal info

6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal

Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.52, p.302-306, 2005

Title: Scintigraphy using 99mTc-MIBI (sestamibi), a sensitive parameter of activity of multiple myeloma

Abstract: Technetium-99m methoxyisobutylisonitrile (99mTc-MIBI) has been shown to be useful in identifying several types of tumors, such as breast, brain, thyroid gland, malignant lymphomas and multiple myeloma. In this study, 102 patients with multiple myeloma (MM) and 32 patients with monoclonal gammopathy of undetermined significance (MGUS) had been evaluated for correlation between 99mTc-MIBI and biochemical and hematological markers of activity of the disease. Significant statistical correlation was found between summary score (SS) of 99mTc-MIBI scintigrams and beta2-microglobulin (p<0.001), monoclonal immunoglobulin level MIG (p<0.001), serum thymidinekinase – sTK (p<0.001), CRP (p 0.05) and cross-linked carboxyterminal telopeptide of type I collagen – ICTP (p<0.05) bone marrow plasmocytosis -BMPc (p<0.001) and hemoglobin Hb (p<0.001). All 32 patients with MGUS had physiological activity of 99mTc-MIBI scintigrams. Technetium-99m methoxyisobutylisonitrile (99mTc-MIBI) is a useful indicator of activity ofMMand helps in differentiating between multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS).

Keywords: Technetium-99-m methoxyisobutylisonitrile, multiple myeloma, monoclonal gammopathy of undetermined significance
Year: 2005, Volume: 52, Issue: Page From: 302, Page To: 306

download file

© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.